Immunome, Inc., a biotechnology company headquartered in Exton, Pennsylvania, has been actively engaged in the development and commercialization of novel therapeutic antibodies and medicines aimed at treating various diseases. The company primarily serves patients within the state of Pennsylvania and operates within the Health Care sector. Immunome’s stock is publicly traded on the Nasdaq stock exchange under the ticker symbol IMMO.
As of February 23, 2026, Immunome’s stock closed at $22.12, reflecting a decline from its 52-week high of $27.65, which was recorded on February 3, 2026. Despite this decline, the stock remains above its 52-week low of $5.15, set on April 8, 2025. This indicates a substantial trading range over the past year, highlighting the stock’s volatility.
The company’s market capitalization stands at approximately $2.41 billion USD. However, valuation metrics present a mixed picture. Immunome’s price-to-earnings (P/E) ratio is currently negative at -7.72, indicating that the company has reported earnings below zero. This negative P/E ratio suggests that investors are cautious about the company’s profitability in the near term. Conversely, the price-to-book (P/B) ratio is 8.99, suggesting that the market values the company at nearly nine times its book equity, which may reflect investor confidence in its future growth prospects.
A recent headline dated February 23, 2026, titled “Immunome-Aktie explodiert nach Merger-Update – Chance für deutsche Anleger?” highlighted a significant price surge following an announcement of a merger. This development underscores the recent volatility in Immunome’s stock price and suggests potential opportunities for investors, particularly those in Germany, as indicated by the headline.
Despite the negative earnings multiple, the technical profile of Immunome’s stock indicates significant upside potential within its historical trading range. However, investors are advised to exercise caution when assessing the intrinsic value of the company, given the current financial metrics.
For more detailed information about Immunome, Inc. and its activities, interested parties can visit the company’s official website at www.immunome.com .
